Tecartus genetically modified autologous T cells for infusion Images
Generic Name: brexucabtagene autoleucel
This medication has been identified as Tecartus genetically modified autologous T cells for infusion. It is supplied by Kite Pharma, Inc.
Tecartus is used in the treatment of Acute Lymphoblastic Leukemia; Mantle Cell Lymphoma and belongs to the drug class miscellaneous antineoplastics. Tecartus genetically modified autologous T cells for infusion is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Tecartus
- Generic Name
- brexucabtagene autoleucel
- Strength
- genetically modified autologous T cells for infusion
- Availability
- Prescription only
- Drug Class
- Miscellaneous antineoplastics
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Kite Pharma, Inc.
- National Drug Code (NDC)
- 71287-0219
See also:
More about Tecartus (brexucabtagene autoleucel)
- Check interactions
- Compare alternatives
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.